The effect of antisense tyrosinase-related protein 1 on melanocytes and malignant melanoma cells

British Journal of Dermatology

Volumn 150, Issue 6, 2004, Pages 1081-1090

  Li, C Y ^a   Gao, T W ^a   Wang, G ^a   Han, Z Y ^a   Shen, Z ^a   Li, T H ^a   Liu, Y F ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antisense tyrosinase related protein 1; Malignant melanoma; Melanocytes

Indexed keywords

ANTIBIOTIC G 418; COMPLEMENTARY DNA; LEVODOPA; LIPOFECTAMINE; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; TYROSINASE RELATED PROTEIN 1;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL LINE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DNA TRANSFECTION; ELECTRON MICROSCOPY; ENZYME ACTIVITY; EUKARYOTE; EXPERIMENTAL MODEL; EXPRESSION VECTOR; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; IN VIVO STUDY; MEASUREMENT; MELANOCYTE; MELANOMA; MELANOMA CELL; MICROSCOPY; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELLS, CULTURED; FLOW CYTOMETRY; HUMANS; MELANOCYTES; MELANOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; OXIDOREDUCTASES; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TRANSFECTION;

EID: 3142671895     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.05929.x     Document Type: Article

References (40)

1. Negroiu G, Dwek RA, Petrescu SM. Folding and maturation of tyrosinase-related protein-1 are regulated by the post-translational formation of disulfide bonds and by N-glycan processing. J Biol Chem 2000; 275: 32200-7.
2. Kobayashi T, Urabe K, Winder A et al. Tyrosinase related protein 1 (TRP-1) functions as a DHICA oxidase in melanin biosynthesis. EMBO J 1994; 13: 5818-25.
3. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994; 180: 1-4.
4. Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med 1990; 171: 1375-80.
5. Vijayasaradhi S, Doskoch PM, Houghton AN. Biosynthesis and intracellular movement of the melanosomal membrane glycoprotein gp75, the human b (brown) locus product. Exp Cell Res 1991; 196: 233-40.
6. Der JE, Dixon WT, Jimbow K, Horikoshi T. A murine monoclonal antibody. MoAb HMSA-5, against a melanosomal component highly expressed in early stages, and common to normal and neoplastic melanocytes. Br J Cancer 1993; 67: 47-57.
7. Boissy RE, Sakai C, Zhao H et al. Human tyrosinase related protein-1 (TRP-1) does not function as a DHICA oxidase activity in contrast to murine TRP-1. Exp Dermatol 1998; 7: 198-204.
8. Hara H, Lee MH, Chen H et al. Role of gene expression and protein synthesis of tyrosinase, TRP-1, lamp-1, and CD63 in UVB-induced melanogenesis in human melanomas. J Invest Dermatol 1994; 102: 495-500.
9. Hearing VJ, Tsukamoto K, Urabe K et al. Functional properties of cloned melanogenic proteins. Pigment Cell Res 1992; 5: 264-70.
10. Kobayashi T, Imokawa G, Bennett DC, Hearing VJ. Tyrosinase stabilization by Tyrp1 (the brown locus protein). J Biol Chem 1998; 273: 31801-5.
11. Jackson IJ, Chambers D, Rinchik EM, Bennett DC. Characterization of TRP-1 mRNA levels in dominant and recessive mutations at the mouse brown (b) locus. Genetics 1990; 126: 451-9.
12. Johnson R, Jackson IJ. Light is a dominant mouse mutation resulting in premature cell death. Nat Genet 1992; 1: 226-9.
13. Salopek TG, Jimbow K. Induction of melanogenesis during the various melanoma growth phases and the role of tyrosinase. lysosome-associated membrane proteins, and p90 calnexin in the melanogenesis cascade. J Invest Dermatol Symp Proc 1996; 1: 195-202.
14. Le Poole IC, Das PK, van den Wijngaard RM et al. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 1993; 2: 145-53.
15. Le Poole C, Boissy RE. Vitiligo. Semin Cutan Med Surg 1997; 16: 3-14.
16. Grimes PE, Ghoneum M, Stockton T et al. T cell profiles in vitiligo. J Am Acad Dermatol 1986; 14: 196-201.
17. Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995; 182: 1609-14.
18. Fishman P, Merimski O, Baharav E, Shoenfeld Y. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Cancer 1997; 79: 1461-4.
19. Ongenae K, Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 90-100.
20. Kemp EH, Waterman EA, Hawes BE et al. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 2002; 109: 923-30.
21. Merimsky O, Shoenfeld Y, Baharav E et al. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo). Hum Antibodies Rybridomas 1996; 7: 151-6.
22. Betterle C, Peserico A, Bersani G. Vitiligo and autoimmune polyendocrine deficiencies with autoantibodies to melanin-producing cells. Arch Dennatol 1979; 115: 364.
23. Hertz KC, Gazze LA, Kirkpatrick CH, Katz SI. Autoimmune vitiligo: detection of antibodies to melanin-producing cells. N Engl J Med 1977; 297: 634-7.
24. Fishman P, Azizi E, Shoenfeld Y et al. Vitiligo autoantibodies are effective against melanoma. Cancer 1993; 72: 2365-9.
25. Merimsky O, Shoenfeld Y, Yecheskel G et al. Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism. Cancer Immunol Immunother 1994; 38: 411-16.
26. Hann SK, Koo SW, Kim JB, Park YK. Detection of antibodies to human melanoma cells in vitiligo and alopecia areata by Western blot analysis. J Dermatol 1996; 23: 100-3.
27. Norris DA, Kissinger RM, Naughton GM, Bystryn JC. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988; 90: 783-9.
28. Cui J, Arita Y, Bystryn JC. Cytolytic antibodies to melanocytes in vitiligo. J Invest Dermatol 1993; 100: 812-15.
29. Abdel-Naser MB, Kruger-Krasagakes S, Krasagakis K et al. Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo. Pigment Cell Res 1994; 7: 1-8.
30. Hedley SJ, Metcalfe R, Gawkrodger DJ et al. Vitiligo melanocytes in long-term culture show normal constitutive and cytokine-induced expression of intercellular adhesion molecule-1 and major histocompatibility complex class I and class II molecules. Br J Dermatol 1998; 139: 965-73.
31. Maresca V, Roccella M, Roccella F et al. Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo. J Invest Dermatol 1997; 109: 310-13.
32. Jimbow K, Chen H, Park JS, Thomas PD. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo. Br J Dermatol 2001; 144: 55-65.
33. Li CY, Gao TW, Liu YF. Gene cloning, expression and purification of human TRP-1. Chin J Derm Venereol 2001; 15: 368-70.
34. Nakajima M, Shinoda I, Fukuwatari Y, Hayasawa H. Arbutin increases the pigmentation of cultured human melanocytes through mechanisms other than the induction of tyrosinase activity. Pigment Cell Res 1998; 11: 12-17.
35. SiTu ZQ, Wu JZ. General knowledge of cell culture. In: Cell Culture (SiTu ZQ, Wu JZ, eds), Beijing: World Book Publishers. 1996: 9-10.
36. Huang CL, Nordlund JJ, Boissy R. Vitiligo: a manifestation of apoptosis? Am J Clin Dermatol 2002; 3: 301-8.
37. Pandey A, Mishra S, Misra K. Immunostimulation: the sense in antisense technology. Indian J Biotechnol 2003; 2: 175-83.
38. Stone LS, Vulchanova L. The pain of antisense: in vivo application of antisense oligonucleotides for functional genomics in pain and analgesia. Adv Drug Deliv Rev 2003; 55: 1081-112.
39. Good L. Diverse antisense mechanisms and applications. Cell Mol Life Sci 2003; 60: 823-4.
40. Vacek M, Sazani P, Kole R. Antisense-mediated redirection of mRNA splicing. Cell Mol Life Sci 2003; 60: 825-33.